Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05794139 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy
A Phase 2 study of Spinal Muscular Atrophy, sponsored by NMD Pharma A/S.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
- 20
- Study locations
NCT05794139: Recruiting Phase 2 study of Spinal Muscular Atrophy, sponsored by NMD Pharma A/S.
NCT05794139 is a Phase 2 study of Spinal Muscular Atrophy that is actively recruiting participants, run by NMD Pharma A/S. The registered enrollment target is 54 participants, below the 107-participant average among 22 other Spinal Muscular Atrophy trials with a reported enrollment target (50% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05794139, a Phase 2 study of Spinal Muscular Atrophy, is actively recruiting participants, sponsored by NMD Pharma A/S.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of NMD670 in the treatment of ambulatory adults with spinal muscular atrophy type 3
Primary Outcome
Distance walked (meters)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG NMD670
Study Locations (20)
Other
- UZ Leuven - Neurochirurgie Campus Gasthuisberg - Leuven
- CHR de la Citadelle - Neurologie - Liège
- Heritage Medical Research Clinic - Calgary
- Genge Partners Inc. - Montreal
- Aarhus Universitetshospital, Neurologisk Afdeling - Aarhus
- Rigshospitalet - Neurologisk Afdeling - Copenhagen
- Charite - Campus Virchow-Klinikum (CVK) - Berlin
- Universitätsklinikum Essen - Klinik Für Neurologie - Essen
California
- UCLA David Geffen School Of Medicine - Neurology - Los Angeles
- Stanford University Medical Center - Palo Alto
Missouri
- Roy Blunt NextGen Precision Health Institute - Columbia
- Washington University School of Medicine - St Louis
Colorado
- University of Colorado Neurology Clinic - Aurora
Florida
- UF Fixel Institute for Neurological Diseases - Gainesville
Georgia
- Rare Disease Center - Atlanta
Kansas
- University of Kansas Medical Center - Kansas City
Maryland
- The Johns Hopkins Medicine, Spinal Muscular Atrophy Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2023-09-21 |
| Est. Completion | 2026-05 |
| Phase | Phase 2 |
What NCT05794139 shows while recruiting
NCT05794139 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 107-participant average among 22 other Spinal Muscular Atrophy trials with a reported enrollment target (50% lower).
The record links to 1 condition, with Spinal Muscular Atrophy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05794139 names 20 study sites across 11 states, led by Other, California, Missouri.
Frequently Asked Questions
What is clinical trial NCT05794139 about?
NCT05794139 is a clinical study titled "Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy". The purpose of this study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of NMD670 in the treatment of ambulatory adults with spinal muscular atrophy type 3
What is the current status of trial NCT05794139?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2023-09-21. Estimated completion is 2026-05.
What conditions does trial NCT05794139 study?
This clinical trial studies the following conditions: Spinal Muscular Atrophy.
What interventions are being tested in trial NCT05794139?
The interventions under investigation include: Placebo (DRUG), NMD670 (DRUG).
Who is sponsoring clinical trial NCT05794139?
This trial is sponsored by NMD Pharma A/S, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05794139 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Spinal Muscular Atrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05794139's enrollment target sits among peer trials
54 12th of 22 higher than 11 of 22 other Spinal Muscular Atrophy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Spinal Muscular Atrophy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy
RECRUITING · Phase 2
-
An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy
COMPLETED · Phase 2
-
A Study of Risdiplam (RO7034067) in Adult and Pediatric Participants With Spinal Muscular Atrophy
COMPLETED · Phase 2
-
Characterizing Perceived Physical Fatigability in Nusinersen-treated SMA
RECRUITING
-
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
RECRUITING · NA
-
Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI